Hypothalamic gonadotrophin-releasing hormone (GnRH) plays a major role in the endocrine control of reproduction. Acting through its high affinity receptors on pituitary gonadotrophs, it regulates the secretion of gonadotrophins. In addition, GnRH also functions as a local regulator in a number of other cell lines and tissues, including the placenta. In a manner analogous to hypothalamic GnRH stimulation of LH and FSH from the anterior pituitary, GnRH was found to cause a dose-dependent release of human chorionic gonadotrophin (HCG) from the placenta. So began the search for a putative GnRH receptor in the human placenta. Although early radio-receptor studies reported specific binding, the properties of these 'putative' GnRH binding sites were found to differ significantly from those of their pituitary counterparts in several important respects. This was followed by a series of contradictory reports that led to more questions and opened up avenues for further investigations. Even after nearly two decades of research, the human placental GnRH receptor has not been characterized beyond all reasonable doubt. This review recalls the discovery, the controversies and unanswered questions concerning the human placental GnRH receptor.
Introduction
synthetic GnRH significantly increased the release of immunoactive human chorionic gonadotrophin (HCG) (for Gonadotrophin-releasing hormone (GnRH) is the key neural reviews, see Siler-Khodr, 1983; Belisle et al., 1984 ; regulator of the reproductive process. GnRH released from the Mathialagan and Rao, 1986a; Lin et al., 1995) . In turn, HCG hypothalamus controls the synthesis and release of LH and stimulates the synthesis and secretion of progesterone from FSH from the pituitary, which, in turn, affects gonadal function. the corpus luteum, which is required for early establishment In the pituitary, the primary site of action of GnRH is the and maintenance of pregnancy. HCG also up-regulates low gonadotroph, the cell that expresses high affinity GnRH density lipoprotein (LDL) receptor expression in the placenta, receptors and secretes gonadotrophic hormones. The interaction thereby enhancing the rate-limiting step in the biosynthesis of between GnRH and its receptor is a critical event in the progesterone, which is indispensable for the maintenance of endocrine regulation of reproduction and therefore, understandpregnancy (Gopi Shanker et al., 1998) . The endocrine response ing the regulation of the GnRH receptor is important for the to exogenous GnRH was dose-dependent, maximal at midstudy of normal reproductive physiology.
gestation, and partly inhibited by an antagonist of GnRH GnRH functions not only as a releasing hormone in the (Siler-Khodr et al., 1983) , indicating the involvement of GnRH pituitary, but is distributed widely throughout the central and receptor-mediated downstream signalling. The release of HCG peripheral nervous system as well as in several extra-neural, following GnRH stimulation (which in turn induces progesterneoplastic and non-reproductive tissues (Hsueh and Jones, one production) is reminiscent of the cascade that operates in 1981; Stojilkovic et al., 1994; Kakar and Jennes, 1995;  Kottler the hypothalamo-pituitary-gonadal axis (Santra et al., 1999 (Santra et al., ). et al., 1999 , where it is believed to be involved in the regulation of cell growth and proliferation.
Placenta produces a decapeptide that is similar to hypothalamic GnRH A role for GnRH in the human placenta A plethora of in-vitro studies have demonstrated a functional Since circulating concentrations of hypothalamic GnRH are far too low to sustain placental production of HCG, it was role for GnRH in placental endocrinology, based on the observation that incubation of human placental minces with proposed that the placenta itself could produce GnRH or GnRH-like peptides and also respond to it. This hypothesis that, although different isoforms were degraded at different rates in these tissues, differences in the ability of the isoforms was confirmed by several in-vitro and in-vivo experiments, some of which are described below.
to bind to placental rather than pituitary sites were not related to differences in degradation of the tracers, but rather to Incubation of placental trophoblasts with radioactive precursors resulted in the synthesis of a physiologically active differences in their specificity for the binding site. Secondly, it was also possible that placental GnRH was decapeptide (Gibbons et al., 1975; Tan and Rousseau, 1982) . The concentration of this GnRH-like substance was found to structurally different from hypothalamic GnRH, in which case the GnRH receptor would have a higher affinity for the correct be higher in the placenta than in the maternal or fetal circulation or amniotic fluid. This decapeptide was found to share strucligand and a lower affinity for both GnRH and the agonist. However, all available evidence, as recalled earlier in this tural, immunological, chemical and biological similarities with hypothalamic GnRH (Gibbons et al., 1975; Siler-Khodr et al., review, supported the view that placental GnRH was indistinguishable from hypothalamic GnRH and therefore this possibil-1983; Mathialagan and Rao, 1986b) . The cDNA sequences of the precursor forms of hypothalamic and placental GnRH were ity seemed unlikely although differential processing of the prepro-GnRH to yield other isoforms of GnRH could not be also shown to be identical (Seeburg and Adelman, 1984; Kelly et al., 1991; Duello et al., 1993) . Early immunofluorescence ruled out. Thirdly, it was also suggested (Currie et al., 1981 ) that studies (Khodr and Siler-Khodr, 1978; Miyake et al., 1982) suggested that cytotrophoblasts of placental villi were the site GnRH or GnRH agonists bind to a placental site, which was in fact a GnRH-degrading enzyme. However, it was later of production of this decapeptide in the placenta. However, recent reports (Wolfahrt et al., 1998) indicate its production demonstrated that this was not so (Menzies and Bramley, 1992) and, by subcellular fractionation of placental tissue by both cytotrophoblasts and syncytiotrophoblasts in first and third trimester placentae.
following density gradient centrifugation, it was shown that while degradation of radiolabelled ligand is associated with placental cytosol fractions, GnRH binding activity was associDiscovery and characterization of human placental GnRH ated largely with placental plasma membranes. binding sites A further possibility remained that besides the presence of high affinity receptors for GnRH, which the study reported, In 1981, for the first time, the presence of the GnRH receptor in the human placenta using radio-receptor assays was reported there are also other receptors for GnRH which are structurally different and whose concentration varies in different sample (Currie et al., 1981) . This was also the first demonstration of extra-pituitary GnRH receptors in the human.
preparations through gestation. This additional possibility was corroborated by other studies Crude membrane preparations from term placentae, placentae at 10-12 weeks gestation and one hydatidiform mole were (Belisle et al., 1984) , which reported multiple binding sites for GnRH in enriched mid-term and term chorionic membrane found to bind GnRH agonists with high affinity and specificity. Native GnRH competed for binding with the same affinity preparations on the strength of binding data. These authors reported high affinity and low affinity binding sites for GnRH. whereas unrelated peptide fragments (oxytocin, thyrotrophinreleasing hormone, somatostatin) gave no or minimal Their results indicated that GnRH agonists and antagonists do not compete with the same receptor sites to displace native displacement. Native GnRH was found to have the same affinity for the placental GnRH receptor as it had for GnRH GnRH and that a population of these binding sites exhibited low affinity for GnRH. This observation was unexpected and receptors in the pituitary cell membranes, rat luteal cells or rat Leydig cells. However, GnRH agonists bound these tissues difficult to explain since, in rat and bovine pituitary radioreceptor assays, inhibitory analogues of GnRH compete with with a 100-fold higher affinity than the placenta. Three possible explanations were offered for this observation.
synthetic GnRH for the same receptor sites. However, despite their low affinity for GnRH, these binding Firstly, the placenta could possibly possess a protease that acts on sites within the agonists not protected by D-amino acid sites were found to be saturable, of low capacity-high specificity for the ligand. The functional relevance of these sites in substitutions and, therefore, the agonists could be degraded to the same extent as placental GnRH. This view was initially the production of bioactive HCG was also demonstrated (Belisle et al., 1984 (Belisle et al., , 1987 . Studies with placental cells from supported by the observation that the amount of [ 125 I]-GnRH agonist bound per mg protein decreased as protein concentraanencephalic fetuses showed a decreased binding capacity for GnRH and its agonists, when compared with normal tion was increased. The following possibility, however, had to be considered. Differences in the abilities of radiolabelled trophoblastic cells, as well as a reduced capacity to produce HCG. These results also suggested that mechanisms dependent GnRH isoforms to bind to rat pituitary and human placental receptors may indeed reflect differential inactivation of tracer upon GnRH binding to its receptor are required for placental HCG production in normal pregnancies. These findings gained during the binding incubation. Therefore, if one tracer were degraded more rapidly during incubation with placental memadditional support from other studies (Iwashita et al., 1986) , which confirmed the existence of low affinity (yet specific) branes than the second, then the former would appear to be less capable of binding. This question was convincingly binding sites for GnRH in human term placentae, again using binding studies. However, further approaches had to be taken addressed by a study of the inactivation of various GnRH tracers following incubation with either rat pituitary or human to determine the biochemical nature of this receptor.
The presence of a 58 kDa binding site for GnRH in human placental membranes (Bramley et al., 1992) . It was shown term placental membranes was demonstrated (Escher et al., placental GnRH receptor message by reverse transcriptionpolymerase chain reaction (RT-PCR) and performed Southern 1988) using photolabelling experiments followed by sodium blotting under high stringency conditions to determine the dodecyl sulphate (SDS) gel electrophoresis. But again, their authenticity of the product obtained. However, in the absence results suggested the association of this 58 kDa binding site of sequence information, it is difficult to conclusively comment with other proteins to form the functional GnRH receptor.
on the extent of identity to the pituitary counterpart. Also, the All studies described so far pointed to the presence of low RT-PCR product that hybridized to the human pituitary cDNA affinity GnRH receptors in the human placenta that are distinct sequence represents only a small fragment (see Table I ). It from the typical high affinity receptors for GnRH present in the is highly likely that corresponding sequences differ outside pituitary. These data, however, did not provide a mechanistic this region. explanation for the regulatory role of GnRH in placental HCG This was soon followed by studies (Wolfahrt et al., 1998) , secretion. Characterization of GnRH receptor gene expression which demonstrated the presence of the GnRH receptor mRNA was required to define the functional role of GnRH in the in human trophoblasts throughout gestation, using in-situ RTregulation of HCG secretion by the placenta and the associated PCR and exon-spanning primers (see Table I ). These results changes with gestational age.
were contradictory to previous studies (Lin et al., 1995) , which Cloning and characterization of the human pituitary GnRH suggested that GnRH receptor mRNA expression decreases receptor (Kakar et al., 1992; Chi et al., 1993) allowed the with gestation and disappears at term. This is perhaps due to availability of cDNAs and, therefore, the use of sensitive the fact that the technique of in-situ RT-PCR used by Wolfahrt assays involving hybridization to radioactive probes.
et al. was more sensitive than in-situ hybridization and could help demonstrate the GnRH receptor message, even in cells Human placental GnRH receptor mRNA expression from term placentae, which earlier studies could not. However, In an attempt to investigate the distribution of the GnRH this study could not determine whether the GnRH receptor receptor gene transcript in the human placenta, in-situ message detected was actually translated into a functional hybridization assays were performed with samples at various protein product. gestational ages (Lin et al., 1995) . GnRH receptor expression
In 1998, the sequence of a human placental cDNA (Boyle could be detected in both cytotrophoblasts and in syncytiotroet al., 1988) was shown to be identical to that of the pituitary phoblasts. The signals were abundant at 6 weeks gestation, GnRH receptor cDNA, as previously reported (Kakar et al. , peaked at 9 weeks, began to decline in the third trimester and, 1992; Chi et al., 1993) . Using specific primers (designed based by term, the signals were undetectable by this assay. Also, the on the human pituitary GnRH receptor cDNA sequence, see responsiveness of placental explants to GnRH stimulation in Table I ), they amplified the human placental GnRH receptor HCG was found to parallel the changing intensity of signals cDNA by RT-PCR and sequenced the clones. This study, at different stages of gestation. This observation was in however, leaves room for doubt. The source of the RT-PCR agreement with the previous binding studies (Bramley et al., products is questionable because the authors have not ruled 1994), which reported that specific GnRH binding activity was out endometrial contamination in the first trimester placental significantly reduced in membranes from placentae recovered samples collected. A myriad of studies, reported over the last at 10-20 weeks gestation, compared with 6-9 weeks. However, decade, have demonstrated the presence of the GnRH receptor to quote Boyle et al., ' it is difficult to assess these results (Lin in the endometrium (Imai et al., 1994a,b; Chatzaki et al., et al., 1995) , since it is not clear whether the sampling was 1996; Raga et al., 1998; Takeuchi et al., 1998) . Since the sufficient and also, non-specific labelling does not appear to endometrium and the placenta are intimately associated with have been subtracted from total labelling' (Boyle et al., 1998) . each other during pregnancy, it is important to ensure the In the same year, other authors (Kakar and Jennes, 1995) absence of endometrial contamination, more so, since even reported the direct demonstration of the human placental GnRH traces of it in placental samples would give a grossly erroneous receptor mRNA. Using primers based on the sequence of the picture of the genes expressed by the placenta, given the sensitivity of the RT-PCR technique. Studies from our laborahuman pituitary GnRH receptor cDNA, they amplified the tory demonstrate that specific endometrial However, we were unable to amplify the human placental sequence using these primers under all conditions tried (unpubmessages can be amplified by RT-PCR from as little as 0.01% contribution from endometrial cDNA. Also, this study (Boyle lished observations) . Using another set of exon-spanning primers, we have amplified and cloned an internal fragment et al., 1988) reported the amplification of the receptor cDNAs from 6 and 8 week placental samples but not from 5 and 7 of the human placental GnRH receptor cDNA (unpublished observations). However, we have not yet been able to obtain a week samples. This is difficult to explain, given that maternal HCG concentrations rise exponentially for the first 6 weeks full-length fragment by RT-PCR. It is possible that the human pituitary and placental sequences differ while being conserved of gestation, peak at weeks 8-10 and only decrease thereafter.
However, discounting the above-mentioned inconsistencies, at the exon-intron junctions so that, amplification occurs only with exon-spanning primers. Furthermore, the failure to amplify the results based on RT-PCR and in-situ hybridization (Kakar and Jennes, 1995; Lin et al., 1995; Boyle et al., 1998 ; Wolfahrt the placental GnRH receptor mRNA consistently at all stages of gestation, using the same set of primers, also suggests that there et al., 1998), indicated that the action of GnRH in the placenta could indeed be mediated through its typical high affinity might be different receptors expressed at different stages of gestation. receptors. These were in sharp contrast to the earlier binding studies that suggested that the receptors might differ. An
In the midst of a sea of unanswered questions and a host of possibilities, it is slowly beginning to dawn why the placental obvious question that had to be addressed was the copy number of the GnRH receptor gene in the human genome. The answer receptor sequence has eluded detection for so long. The technical modifications (e.g. nested PCR or reamplification PCR) to this question made explanations to the above observations more difficult. Genomic Southern blot analysis indicated its described in the previous reports (Boyle et al., 1998; Wolfahrt et al., 1998) , to amplify the sequence, suggest that either the presence in a single copy (Fan et al., 1994) . However, since the human GnRH receptor gene has multiple transcription sites
GnRH receptor mRNA is a rare transcript or it may have a very short half-life. It is also possible that GnRH receptor mRNA and polyadenylation signals (Fan et al., 1995) , it is possible that there may be a differential usage of promoter and/or may be translated as rapidly as it is transcribed, with the result that the net accumulation of mRNA within the cell, at any given polyadenylation signals. In a preliminary study (Rodway et al., 1995) the detection of GnRH receptor transcript in the human point in time, is below the limits of detection. Again, our own observations (unpublished data) are also in concord with these placenta was described (for review, see Leung and Peng, 1996) . Unlike in the pituitary where a major transcript of and contrary to those of Kakar and Jennes (1995) , who reported detection of this mRNA species without the need for any special 4.7-5 kb was found (Kakar et al., 1992; Chi et al., 1993) , Northern blot analysis of human placental tissue, as well as two technical modifications to enrich GnRH receptor mRNA in the total RNA pool. Perhaps more extensive sampling and screening placental choriocarcinoma cell lines, JEG-3 and JAR, revealed a major transcript of 1.2 kb.
of placental libraries might reveal additional forms present in small amounts. This is highly probable, considering a previous A further possible explanation for this discrepancy could involve the presence of multiple transcripts for the human plareport (Troskie et al., 1998) . Their study using PCR amplification of genomic DNA with degenerate primers (designed to amplify cental GnRH receptor gene that may arise due to alternative splicing. This is possible because the open reading frame in this the extracellular loop 3), supports the concept of existence of multiple GnRH receptor sub-types in vertebrates. Again, gene is distributed among three exons. Alternative splicing is known to occur in numerous members of the G-protein-coupled whether there does truly exist more than one physiologically significant form of the receptor, only time will tell. receptor family, and is correlated with differences in affinity, potency, coupling efficiency, specificity, subcellular localization or sensitivity to desensitization of the receptor. Interestingly, Conclusions such variant transcripts, differing in their sequence, have been described for the mouse and human pituitary GnRH receptor
The characterization of the human placental GnRH receptor is of utmost importance because it contributes directly to the study gene (Zhou and Sealfon, 1994; Grosse et al., 1997) . Variant transcripts of the GnRH receptor gene have also been shown to of HCG regulation and hence, to our understanding of placental endocrinology. Ever since the discovery of GnRH binding sites exhibit a tissue-specific pattern of expression (Kottler et al., 1999) . The functional relevance of these variant transcripts is, in the human placenta, a myriad of studies have attempted to characterize the 'putative' receptor. Early studies based on radiohowever, a matter of speculation. Even if the sequence of the transcripts turns out to be identical, the encoded proteins could receptor assays revealed that GnRH agonists bind the placental site with a much lower affinity than they bind the corresponding perhaps differ in their post-translational processing, yielding proteins that differ in their phosphorylation or glycosylation sites on pituitary cells. These results suggested that the receptors might differ. In sharp contrast to the binding data, recent reports states. Multiple receptor isoforms, if present, could modulate the function of GnRH by exhibiting variable affinities and could based on RT-PCR and in-situ hybridization assays suggest that the human pituitary and placental GnRH receptors may indeed therefore explain earlier binding data in the light of recent observations made on the strength of RT-PCR and in-situ hybridizabe identical. This is difficult to explain, considering the fact that the GnRH receptor gene exists as a single copy gene in the tion assays. Studies from our laboratory also support this possibility. Using primers based on the sequence of the human human genome. However, a careful analysis of the gene structure points to several possibilities for this observation. The utilization pituitary GnRH receptor cDNA, we have amplified and cloned the bonnet monkey pituitary GnRH receptor (Santra et al., 2000) .
of multiple transcription sites, polyadenylation signals and splice
